The cognitive psychopharmacology of Alzheimer's disease: Focus on cholinergic systems

Neurochemical Research

Volumn 23, Issue 5, 1998, Pages 787-794

  Lawrence, Andrew D ^a,b   Sahakian, Barbara J ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UK   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alzheimer's disease; Attention; Cholinergic; Memory; Psychopharmacology

Indexed keywords

NICOTINE; TACRINE;

ACETYLCHOLINE BRAIN LEVEL; ALZHEIMER DISEASE; ARTICLE; ATTENTION; CHOLINERGIC NERVE; CHOLINERGIC SYSTEM; DRUG USE; HUMAN; MEMORY; PRIORITY JOURNAL;

ACETYLCHOLINE; ALZHEIMER DISEASE; BRAIN; CHOLINERGIC AGENTS; CHOLINERGIC FIBERS; COGNITION; COGNITION DISORDERS; HUMANS; NEUROTRANSMITTER AGENTS;

EID: 0031898636     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022419712453     Document Type: Article

References (86)

1. Selkoe, D. J. 1997. Alzheimer's disease: genotypes, phenotype, and treatment. Science 275:630-631.
2. Robbins, T. W., Elliott, R., and Sahakian, B. J. 1996. Neuropsychology - dementia and affective disorders. British Medical Bulletin 52:627-643.
3. Hodges, J. R., and Patterson, K. 1995. Is semantic memory consistently impaired early in the course of Alzheimer's disease? neuroanatomical and diagnostic implications. Neuropsychologia 33: 441-459.
4. Zec, R. F. 1993. Neuropsychological functioning in Alzheimer's disease. Pages 3-80 in Parks, R. W., Zee, R. F., Wilson, R. S. (eds), Neuropsychology of Alzheimer's Disease and Other Dementias, Oxford UP, New York.
5. Parasuraman, R., and Haxby, J. V. 1993. Attention and brain function in Alzheimer's disease: a review. Neuropsychology 7:242-272.
6. Sahakian, B. J., Jones, G. M. M., Levy, R., Gray, J. A., and Warburton, D. M. 1989. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer's type. British Journal of Psychiatry 154:797-800.
7. Brazzelli, M., Cocchini, G., Della Salla, S., and Spinnler, H. 1994. Alzheimer patients show a sensitivity decrement over time on a tonic alertness task. Journal of Clinical and Experimental Neuropsychology 16:851-860.
8. Parasuraman, R., Greenwood, P. M., Haxby, J. V., and Grady, C. L. 1992. Visuospatial attention in dementia of the Alzheimer type. Brain 115:711-733.
9. Oken, B. S., Kishiyama, M. A., Kaye, J. A., and Howieson, D. B. 1994. Attention deficit in Alzheimer's disease is not simulated by an anticholinergic/antihistaminergic drug and is distinct from deficits in healthy aging. Neurology 44:657-662.
10. Parasuraman, R., Greenwood, P. M., and Alexander, G. E. 1995. Selective impairment of spatial attention during visual search in Alzheimer's disease. Neuroreport 6:1861-1864.
11. Maruff, P., Malone, V., and Currie, J. 1995. Asymmetries in the covert orienting of visual spatial attention to spatial and nonspatial cues in Alzheimer's disease. Brain 118:1421-1435.
12. Scinto, L. F. M., Daffner, K. R., Castro, L., Weintrub, S., Vavrik, M., and Mesulam, M. M. 1994. Impairment of spatially directed attention in patients with probable Alzheimer's disease as measured by eye movements. Archives of Neurology 51:682-688.
13. Sahakian, B. J., Downes, J. J., Eagger, S., Evenden, J. L., Levy, R., Philpot, M. P., Roberts, A. C., and Robbins, T. W. 1990. Sparing of attentional relative to mnemonic function in a subgroup of patients with dementia of the Alzheimer type. Neuropsychologia 28:1197-1213.
14. Lawrence, A. D., and Sahakian, B. J. 1995. Alzheimer disease, attention and the cholinergic system. Alzheimer Disease and Associated Disorders 2:s43-s49.
15. Greenwood, P. M., Parasuraman, R., and Alexander, G. E. 1997. Controlling the focus of spatial attention during visual search: effects of advanced aging and Alzheimer disease. Neuropsychology 11:3-12.
16. Mesulam, M. M. 1996. The systems-level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer's disease. Progress in Brain Research 109:285-297.
17. Everitt, B. J., Sirkia, T. J., Roberts, A. C., Jones, G. H., and Robbins, T. W. 1988. Distribution and some projections of cholinergic neurones in the brain of the common marmoset. Journal of Comparative Neurology 271:533-558.
18. Geula, C., and Mesulam, M. M. 1996. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cerebral Cortex 6:165-177.
19. Wurtman, R. J., Blusztajn, J. K., and Ulus, I. H. 1990. Choline metabolism in cholinergic neurons: implications for the pathogenesis of neurodegenerative diseases. Pages 117-125 in Wurtman, R. J., Corkin, S., Growdon, J. H., Ritter-Walker, E. (eds.), Advances in Neurology. Alzheimer's disease, Raven Press, New York.
20. Bartus, R. T., Dean, R. C., Pontecorvo, M. J., and Flicker, C. 1985. The cholinergic hypothesis: a historical review, current perspectives and future directions. Annals of the New York Academy of Sciences 444:332-358.
21. Perry, E. K., Tomlinson, B. E., Blessed, G., Bergman, K., Gibson, P. H., and Perry, R. H. 1978. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. British Medical Journal 2:1457-1459.
22. Wilcock, G. K., Esiri, M. M., Bowen, D. M., and Smith, C. C. T. 1982. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. Journal of the Neurological Sciences 57:407-417.
23. Palmer, A. M., Francis, P. T., Bowen, D. M., Benton, J. S., Neary, D., Mann, D. M. A., and Snowden, J. S. 1987. Catecholaminergic neurons assessed antemortem in Alzheimer's disease. Brain Research 414:365-375.
24. Lehericy, S., Hirsch, E. C., Cervera-Pierot, P., Hersh, L. B., Bakchine, S., Piette, F., Duyckaerts, C., Hauw, J-J., Javoy-Agid, F., and Agid, Y. 1993. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. Journal of Comparative Neurology 330: 15-31.
25. Drachman, D. A., and Sahakian, B. J. 1979. Effects of cholinergic agents on human learning and memory. Pages 351-366 in Barbeau, A., Growden, J. H., Wurtman, R. J. (eds.), Nutrition and the Brain: volume 5, Raven Press, New York:351-366.
26. Sahakian, B. J. 1988. Cholinergic drugs and human cognitive performance. Pages 393-424 in Iversen, L. L., Iversen, S. D., Snyder, S. H. (eds.), Handbook of Psychopharmacology Volume 20, Plenum, New York:393-424.
27. Sahakian, B. J., and Jones, G. M. M. 1991. Cholinergic drugs and human cognitive performance. pages 65-86 in Weinman, J., Hunter, J. (eds.), Memory: Neurochemical and Abnormal Perspectives, Harwood, London:65-86.
28. Aarsland, D., Larsen, J. P., Reinvang, I., and Aasland, A. M. 1994. Effects of cholinergic blockade on language in healthy young women: implications for the cholinergic hypothesis in dementia of the Alzheimer type. Brain 117:1377-1384.
29. Dunnett, S. B., Everitt, B. J., and Robbins, T. W. 1991. The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions. Trends in Neurosciences 14: 494-501.
30. Robbins, T. W., McAlonan, G., Muir, J. L., and Everitt, B. J. 1997. Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. Behavioural Brain Research 83:15-23.
31. Voytko, M. L. 1996. Cognitive functions of the basal forebrain cholinergic system in monkeys: memory or attention? Behavioural Brain Research 75:13-25.
32. Torres, E. M., Perry, T. A., Blokland, A., Wilkinson, L. S., Wiley, R. G., Lapp, D. A., and Dunnett, S. B. 1994. Behavioural, histochemical and biochemical consequences of selective immunolesions in discrete regions of the basal forebrain cholinergic system. Neuroscience 63:95-122.
33. Wenk, G. L., Stoehr, J. D., Quintana, G., Mobley, S., and Wiley, R. G. 1994. Behavioral, biochemical, histological, and electrophysiological effects of 192 IgG-Saporin injections into the basal forebrain of rats. Journal of Neuroscience 14:5986-5995.
34. Voytko, M. L., Olton, D. S., Richardson, R. T., Gorman, L. K., Tobin, J. R., and Price, D. L. 1994. Basal forebrain lesions in monkeys disrupt attention but not learning and memory. Journal of Neuroscience 14:167-186.
35. Drachman, D. A., and Sahakian, B. J. 1980. Memory, aging and pharmacosystems. Pages 347-368 in Stein, D. (ed.). The Psychobiology of Aging: Problems and Perspectives, Elsevier, Amsterdam.
36. Richardson, R. T., and Delong, M. R. 1991. Functional implications of tonic and phasic activity changes in nucleus basalis neurons. Pages 135-166 in Richardson, R. T. (ed.). Activation to acquisition. Functional aspects of the basal forebrain cholinergic system, Birkhauser, Boston.
37. Robbins, T. W., and Everitt, B. J. 1995. Arousal systems and attention. Pages 703-720 in Gazzaniga, M. S. (ed.) The cognitive neurosciences, MIT Press, Massachusetts.
38. Thal, L. J. 1991. Physostigmine in Alzheimer's disease. Pages 209-215 in Becker, R., Giacobini, E., (eds.) Cholinergic basis for Alzheimer therapy, Birkhauser, Boston.
39. Muramoto, O., Sugishita, M., and Ando, K. 1984. Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry 47:485-491.
40. Sahakian, B. J., Joyce, E. M., and Lishman, W. A. 1987. Cholinergic effects on constructional abilities and on mnemonic processes: a case report. Psychological Medicine 17:329-333.
41. Jacobs, D. H., Shuren, J., Gold, M., Adair, J. C., Bowers, D., Williamson, D. J. G., and Heilman, K. M. 1996. Physostigmine pharmacotherapy for anomia. Neurocase 2:83-91.
42. Thal, L. J. 1996. Cholinomimetic treatment of Alzheimer's disease. Progress in Brain Research 109:299-309.
43. Lawrence, A. D., and Sahakian, B. J. 1996. The neuropsychology of frontostriatal dementias. Pages 243-265 in Woods, R. T. (ed.). Handbook of the clinical psychology of ageing, Chichester, Wiley.
44. Robbins, T. W., James, M., Owen, A. M., Sahakian, B. J., McInnes, L., and Rabbitt, P. 1994. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 5:266-281.
45. Roberts, A. C., and Sahakian, B. J. 1993. Comparable tests of cognitive function in monkey and man. Pages 165-184 in Sahgal, A. (ed.) Behavioural neuroscience: a practical approach, IRL Press, Oxford.
46. Sahakian, B. J., Owen, A. M., Morant, N. J., Eagger, S. A., Boddington, S., Crayton, L., Crockford, H. A., Crooks, M., Hill, K., and Levy, R. 1993. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology 110:395-401.
47. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. 1985. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34:939-944.
48. Perry, E. K., Morris, C. M., Court, J. A., Cheng, A., Fairburn, A. F., McKeith, I. G., Irving, D., Brown, A., and Perry, R. H. 1995. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 64:385-395.
49. Nordberg, A. 1996. Pharmacological treatment of cognitive dysfunction in dementia disorders. Acta Neurologica Scandinavia 168:s87-s92.
50. 3H-acetylcholine release from mouse cerebral cortical synaptosomes. Journal of Neurochemistry 43:1593-1598.
51. Heishman, S. J., Taylor, R. C., and Henningfield, J. E. 1994. Nicotine and smoking: a review of effects on human performance. Experimental and Clinical Psychopharmacology 2:345-395.
52. Jones, G. M. M., Sahakian, B. J., Levy, R., Warburton, D. M., and Gray, J. A. 1992. Effects of subcutaneous nicotine on atten-tion, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 108:485-494.
53. Snaedal, J., Johannesson, T., Jonsson, J. E., and Gylfadottir, G. 1996. The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease. Dementia 7:47-52.
54. Wilson, A. L., Langley, L. K., Monley, J., Bauer, T., Rottunda, S., McFalls, E., Kovera, C., and McCarten, J. R. 1995. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacology, Biochemistry, and Behaviour 51:509-514.
55. Newhouse, P., Potter, A., and Corwin, J. 1996. Effects of nicotinic cholinergic agents on cognitive functioning in Alzheimer's and Parkinson's disease. Drug Development Research 38:278-289.
56. Parks, R. W., Becker, R. E., Rippey, R. F., Gilbert, D. G., et al. 1996. Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: a pilot double blind transdermal nicotine PET study. Neuropsychology Review 6:61-79.
57. Murray, E. A. 1996. What have ablation studies told us about the neural substrates of stimulus memory? Seminars in the Neurosciences 8:13-22.
58. Posner, M. I., and Dehaene, S. 1994. Attentional networks. Trends in Neurosciences 17:75-79.
59. Sarter, M., and Bruno, J. P. 1997. Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers. Behavioural Brain Research 83:7-14.
60. Cummings, J. L., and Kaufer, D. 1996. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 47:876-883.
61. Chu, C.-C., Tranel, D., Damasio, A. R., and Van Hoesen, G. W. 1997. The autonomic-related cortex: pathology in Alzheimer's disease. Cerebral Cortex 7:86-95.
62. Aggleton, J. P. 1993. The amygdala: neurobiological aspects of emotion, memory, and mental dysfunction. Wiley-Liss, New York.
63. Perry, E. K., Tomlinson, B. E., Blessed, G., Perry, R. H., Cross, A. J., and Crow, T. J. 1981. Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease. Journal of the Neurological Sciences 51:279-287.
64. 2-noradrenergic mechanisms to prefrontal cortical cognitive function. Archives of General Psychiatry 53:448-455.
65. Bierer, L. M., Aisen, P. S., Davidson, M., Ryan, T. M., Stern, R. G., Schmeidler, J., and Davis, K. L. 1993. A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer's disease. Alzheimer Disease and Associated Disorders 7:98-104.
66. Bierer, L. M., Aisen, P. S., Davidson, M., Ryan, T. M., Schmeidler, J., and Davis, K. L. 1994. A pilot study of clonidine plus physostigmine in Alzheimer's disease. Dementia 5:243-246.
67. Mohr, E., Schlegel, J., Fabbrini, G., Williams, J., Mouradian, M., Mann, U. M., Claus, J. J., Fedio, P., and Chase, T. N. 1989. Clonidine treatment of Alzheimer's disease. Archives of Neurology 46:376-378.
68. Schlegel, J., Mohr, E., Williams, J., Mann, U., Gearing, M., and Chase, T. N. 1989. Guanfacine treatment of Alzheimer's disease. Clinical Neuropharmacology 12:124-128.
69. Coull, J. T., Sahakian, B. J., and Hodges, J. R. 1996. The alpha2 antagonist, idazoxan, remediates certain attentional and and executive dysfunction in patients with dementia of frontal type. Psychopharmacology 3:209-249.
70. Nitsch, R. M., Slack, B. E., Wurtman, R. J., and Growdon, J. H. 1992. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Nature 258:304-307.
71. Soininen, H., Kosunen, O., Helisalmi, S., Mannermaa, A., Pal-jarvi, L., Talasniemi, S., Ryynanen, M., and Riekkinen, P. 1995. A severe loss of choline-acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon-4 allele. Neuroscience Letters 187:79-82.
72. Riekkinen, P., Soininen, H., Partanen, J., Paakkonen, A., Helisalmi, S., and Riekkinen, P. 1997. The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients. Psychopharmacology 129:285-288.
73. Van Duijin, C. M., and Hofman, A. 1991. Relationship between nicotine intake and Alzheimer's disease. British Medical Journal 302:1491-1494.
74. Perry, E. K., Haroutunian, V., Davis, K. L. et al. 1994. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 5:747-749.
75. Levy, R., Eagger, S., Griffiths, M., Perry, E. K., Honavar, M., Dean, A., and Lantos, P. 1994 Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 343:176.
76. Fagerstrom, K. O., Pomerleau, O., Giordani, B., and Stelson, F. 1994. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology 166:117-119.
77. Levin, E. D., Connors, C. K., Sparrow, E., Hinton, S. C., Erhardt, D., Meck, W. H., Rose, J. E., and March, J. 1996. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacology 123:55-63.
78. Freedman, R., Adler, L. E., Bickford, P., Byerley, W., Coon, H., Cullum, C. M., Griffith, J. M., Harris, J. G., Leonard, S., Miller, C., Myles-Worsley, M., Nagatomo, H. T., Rose, G., and Waldo, M. 1994. Schizophrenia and nicotinic receptors. Harvard Review of Psychiatry 2:179-192.
79. Dursun, S. M., Revely, M. A., Bird, R., and Stirton, F. 1994. Longlasting improvement of Tourette's syndrome with transder mal nicotine. Lancet 337:989-992.
80. Bryson, H. M., and Benfield, P. 1997. Donepezil. Drugs & Aging 10:234-239.
81. Rogers, S. L., and Friedhoff, L. T., Donepezil Study Group. 1996. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 7:293-303.
82. Arendt, T., Schindler, C., Bruckner, M. K., Eschrich, K., Bigl, V., Zedlick, D., Marcova, L. 1997. Plastic neuronal remodelling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. Journal of Neuroscience 17:516-529.
83. Poirer, J., Delisle, M. C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Bertrand, P., Nalbantoglu, J., Gilfix, B. M., and Gauthier, S. 1995. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proceedings of the National Academy of Sciences, USA 92: 12260-12264.
84. Pedersen, W. A., Kloczewiak, M. A., and Blusztajn, J. K. 1996. Amyloid beta-protein reduces acetylcholine synthesis in a cell-line derived from cholinergic neurons of the basal forebrain. Proceedings of the National Academy of Sciences, USA 93:8068-8071.
85. Kar, S., Seto, D., Gaudreau, P., and Quirion, R. 1996. Beta-amyloid -related peptides inhibit potassium-evoked acetylcholine-release from rat hippocampal slices. Journal of Neurosciences 16: 1034-1040.
86. Alhainen, K., and Riekkinen, P. J. 1993. Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurological Scandinavica 88:s16-s21.